sanofi bullous pemphigoid - Search News

Dupixent, Regeneron and bullous pemphigoid

GlobalData on MSN · 3d

FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues.

Dupilumab Under FDA Priority Review for Bullous Pemphigoid

Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

MarketWatch · 4d

Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Bullous Pemphigoid

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 inflammation characterized by intense itch and blisters, reddening of the skin and painful lesions.

Business Insider · 4d

Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only

Sanofi and Regeneron’s Dupixent granted FDA priority review for bullous pemphigoid

Sanofi and Regeneron’s Dupixent (dupilumab) has been accepted for priority review by the US Food and Drug Administration (FDA) to treat adults with bullous pemphigoid (BP).

Can Dupixent plug treatment gap in bullous pemphigoid?

Bullous pemphigoid (BP), which has no FDA-approved targeted therapies, leads to reddening of the skin and the formation of ...

Sanofi nears selling 50 percent controlling stake in Opella to CD&R

Paris: Sanofi and CD&R have announced that they have signed the share purchase agreement in relation to the sale of a 50 ...

4d

Regeneron, Sanofi announce Dupixent sBLA accepted for priority review by FDA

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application for ...

Rx Rundown: Moderna, Sanofi, GSK and more

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

Zacks.com on MSN21h

IONS’ Better-Than-Expected Q4 Results

EC approves MRK's Welireg for two indications. FDA grants priority review to SNY and REGN's Dupixent sBLA for bullous pemphigoid.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results